Measurable residual disease (MRD) is emerging as an important prognostic marker in the management of multiple myeloma. Promising clinical evidence from trials, such as the MYELOMA XI trial, has linked MRD-negativity to improved outcomes in myeloma. Whilst research into MRD as a prognostic marker continues, MRD is further being explored as a tool to guide the adaptive treatment of patients, such as by intensifying treatment for MRD-positive patients, or by de-escalating treatment for MRD-negative patients. Future trials investigating the relative safety and efficacy of MRD-guided adaptive treatment will help to determine the optimal role of MRD in multiple myeloma.
In this podcast, Natalie Callander, MD, of the University of Wisconsin School of Medicine and Public Health, Madison, WI, Luciano Costa, MD, PhD, of the UAB School of Medicine, Birmingham, AL, Fredrik Schjesvold, MD, PhD, of the Oslo Myeloma Center Oslo University, Oslo, Norway, Lanny Kirsch, MD, Senior Vice President in Translational Medicine at Adaptive Biotechnologies, Seattle, WA, and Philippe Moreau, MD, of the Nantes University Hospital, Nantes, France, discuss the latest data on the use of MRD in the management and treatment of multiple myeloma, as presented at the 18th International Myeloma Workshop (IMW 2021).
The AML Sessions: highlights from ASCO/EHA 2021
EHA 2021: key trial updates in myeloma
Key updates on CAR-T therapy for ALL
The Myeloma Sessions: post-COMY 2021 myeloma patients session
EHA 2021: MRD in myeloma
Latest updates on CAR-T therapy for CLL
The Myeloma Sessions: post-COMy 2021 roundtable
Focus on ALL: treating older patients, Ph-like ALL & post-transplant interventions
MDS Session: Women in Science
Key updates on CAR-T & cellular therapy for AML
The MDS Sessions: highlights from ASH 2020
The Transplant Sessions: ASH 2020 highlights
The Lymphoma Sessions: ASH 2020 highlights
Latest updates in Hodgkin lymphoma from ISHL HL 2021
The Myeloma Sessions: Post-ASH 2020 UK Discussion
The Post-EBMT for Trainees VJSessions
Post-ASH Amyloidosis Session from VJHemOnc
The Post EBMT VJSessions from VJHemOnc
Post-EBMT Highlights in Acute Myeloid Leukemia
The CLL Sessions: highlights from ASH 2020
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive